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Abnormal Uterine Bleeding in Adolescents: Treatment
with Combined Oral Contraceptive Pills is Effective Even
in Hospitalized Patients with Bleeding Disorders
Aims: To show the efficacy of oral contraceptive (OC) treatment for hospitalized adolescent patients with
abnormal uterine bleeding (AUB).
Materials and Methods: Thirty-one girls with AUB and anemia hospitalized within the last two years were
included. The patients’ medical records were evaluated retrospectively. All patients were given combined OC
containing 0.03 mg ethinyl estradiol plus 0.15 mg desogestrel according to a defined protocol.
Results: Among 31 patients, 8 (25.8%) had bleeding disorders: 3 (9.7%) had factor VII deficiency, 3 (9.7%)
thrombocytopenia, 1 (3.2%) factor VIII deficiency and 1 (3.2%) von Willebrand disease. Vaginal bleeding
stopped in all patients within a few days with the treatment protocol.
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Conclusions: Adolescents are good responders to medical treatment despite the presence of bleeding
disorders, probably due to the positive coagulative effect of the estrogen component of OCs on platelets and
clotting factors. Continuation of OC will be a problem in adolescent girls, because there are some
misconceptions about OC in the Turkish population, such as that OC can cause infertility or hormonal
imbalance. Appropriate counselling is necessary to overcome this difficulty. We believe that the presence of an
Adolescent Gynecology Unit affected the success of our treatment.
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Anormal Uterus Kanamalı Ergenlerde Kombine Oral Kontraseptif Haplarla
Tedavi, Hastaneye Yatırılan Kanama Bozukluğu olan Hastalarda bile Etkindir
Amaç: Anormal uterus kanamalı (AUK) hastaneye yatırılan adolesan hastalarda oral kontraseptif (OK)
tedavisinin etkinliğini göstermek
Yöntem ve Gereç: Son iki yıl içinde hastaneye yatırılan AUKlı ve anemisi olan 31 genç kız çalışmaya dahil
edildi. Hasta kayıtları geriye dönük değerlendirildi. Bütün hastalara 0.03 mg etinil östradiol ve 0.15 mg
desogestrel içeren OK belirli bir protokole göre verildi.
Bulgular: Otuz bir hastanın 8’inde (% 25.80) kanama bozukluğu vardı: üçünde (% 9.67) faktör VII eksikliği,
üçünde (% 9.67) trombositopeni, birinde (% 3.22) faktör VIII eksikliği ve birinde de (% 3.22) von Willebrand
hastalığı mevcuttu. Tedavi ile bütün hastaların kanamaları birkaç günde durdu.
Sonuç: Adolesanlar kanama bozukluğuna sahip olsalar bile tıbbi tedaviye iyi yanıt verirler. Bu, muhtemelen OK
nın estrojen bileşeninin trombositler ve pıhtılaşma faktörleri üzerindeki pozitif pıhtılaştırıcı etkisine bağlıdır.
Türk toplumunda OK lerin infertiliteye veya hormon dengesizliklerine yol açtığı gibi yanlış inanışlar yüzünden
adolesan kızlarda OK tedavisine devam etmek sorun olabilir. Bu güçlüğün üstesinden gelmek için uygun
danışmanlık vermek gereklidir. Biz Adolesan Jinekolojisi Birimimizin olmasının tedavi başarımızı etkilediğine
inanıyoruz.
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Introduction
Dysfunctional uterine bleeding (DUB) is defined as abnormal endometrial bleeding in
the absence of pelvic pathology and is usually associated with anovulation. DUB
commonly presents within two years of menarche, when more than 50% of cycles are
anovulatory. The presentation varies from heavy prolonged menses interspersed with
long periods of amenorrhea to heavy, frequent bleeding occurring every 1 to 2 weeks.
Because the presentation of DUB is similar to that of many pelvic lesions, it should be
diagnosed only after other causes of bleeding have been excluded (1).
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Abnormal uterine bleeding (AUB) is occasionally the
initial presentation of a blood dyscrasia or coagulation
defect. Management of AUB depends on the severity of
the bleeding and hemoglobin level. In this article, we
present adolescent cases with AUB who required
hospitalization during the last two-year period and
discuss the etiology and management.

Materials and Methods
The prevalence of AUB in 2005 was calculated by
examining the medical records of our hospital’s
Adolescent Gynecology Unit. Percentages of AUB
according to age groups were given.
Thirty-one adolescent patients who were hospitalized
with the diagnosis of AUB and anemia during the last two
years were included in the analysis. This study was in
accordance with the Helsinki Declaration. All the patients’
medical records were evaluated retrospectively.
All patients were assessed for age, age at menarche,
lowest hemoglobin (Hb) level during hospitalization, past
history of medical or surgical problems, treatment carried
out (including surgical intervention) and the details of
hematologic investigation. Transabdominal pelvic
ultrasonographic examination was performed in all
patients. Their hormonal status, including thyroid
function tests, and blood biochemistry were evaluated.
The patients were divided into two groups: the first
group was composed of 23 patients with no bleeding
disorder and the second group of 8 patients with bleeding
disorder. The groups were compared for period of
bleeding, Hb level, body mass index (BMI), age, and age
at menarche. Statistical analysis was done using MannWhitney U test and Statistical Package for Social Sciences
(SPSS) 10.0 for Windows, and P<0.05 was accepted as
indicating statistical significance.
All patients were given combined oral contraceptive
pill containing 0.03 mg ethinyl estradiol plus 0.15 mg
desogestrel (Desolett ®, Organon Ilaclari A.S., Istanbul –
Turkey) as follows: The initial dose was four times a day
for 3 days, then three times a day for 3 days, and then
twice daily for 3 days. Treatment was then continued as
once daily for 12 days to complete the first 21 days of
treatment. After 7 days off the hormones, treatment was
continued as once daily for 21 days, and then no pills for
7 days. The treatment was continued for at least 3 cycles.
432
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This protocol was routinely given at our hospital for the
treatment of AUB in adolescents. The parents of the
adolescents were informed about the therapy and
provided signed informed consent before hospitalization
of the patient.

Results
During 2005, 2171 patients aged 10–19 were
followed in the Adolescent Gynecology Unit of our
hospital. Of these patients, menstrual disorders were
found in 725 (33.4%). While the prevalence of menstrual
disorders was about 48% between the ages 12–15, this
figure was 40.8% at the age of 16-17, and then declined
to 25% at the age of 18-19. One hundred and twenty
(16.6%) of 725 were diagnosed as having AUB. Twenty
of these 120 (16.7%) required hospitalization because of
AUB plus anemia. As a result, 2.8% of adolescents with
menstrual disorders had AUB severe enough to require
hospitalization in 2005.
A total of 31 adolescent patients were hospitalized for
AUB during 2005-2006. The average age of the patients
was 15.3 (12–19) years. There were no medical or
surgical problems in their history, but 4 (12.9%) patients
had bleeding disorders in their family history. The mean
period of bleeding was 22.6±20.0 days (4–90 days),
systolic blood pressure was 102.3±11.3 mmHg
(85–120) and diastolic blood pressure was 65.6±8.1
mmHg (50–80) upon admission. On ultrasonographic
examination, the mean endometrial thickness was
5.2±2.4 mm (2-13). Eighteen of the patients (58.1%)
had endometrial thickness <4 mm. There were no
abnormalities on thyroid function tests or blood
biochemistry.
There were 8 patients (25.8%) with bleeding
disorders: 3 (9.7%) had factor VII deficiency, 3 (9.7%)
3
thrombocytopenia (with platelet count <100,000/mm ),
1 (3.2%) factor VIII deficiency, and 1 (3.2%) von
Willebrand (vWD) disease.
The comparison of patients with and without bleeding
disorders is presented in Table. There were significant
differences between the groups in systolic and diastolic
blood pressures on admission and Hb levels.
The mean Hb level was 7.9±2.4 (3–10.5) g/dL. Of 21
patients with Hb <10 g/dL, 8 (38.1%) had bleeding
disorder, whereas there was no bleeding diathesis among
the patients with Hb ≥10 g/dL.
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Table. Comparison of the groups with and without bleeding disorders with respect to various parameters.

Bleeding Disorder

Period of Bleeding (days)

Absent
N=23
(mean±SD)

Present
N=8
(mean±SD)

P

19.95±17.41

30.25±25.91

0.21

Hemoglobin (g/dL)

8.54±2.35

6.23±1.84

0.01*

BMI (kg/m2)

21.25±1.39

20.69±1.51

0.34

Age (years)

15.43±2.35

14.87±1.64

0.54

Age at Menarche (years)

13.08±0.84

13.12±0.99

0.91

Systolic Blood Pressure (mmHg)

105.43±10.65

93.12±7.98

0.006*

Diastolic Blood Pressure (mmHg)

67.60±7.95

60.00±5.97

0.02*

Endometrial Thickness (mm)

5.30±3.28

4.85±3.53

0.75

* Statistically significant difference (Mann-Whitney U test).

Sixteen patients (51.6%) required blood transfusions.
Of these, 7 (43.8%) had bleeding disorder. Of the 15
patients who did not have blood transfusion, only 1
(6.7%) had bleeding disorder.
Vaginal bleeding stopped in all patients within a few
days with the treatment regimen. One of the
thrombocytopenic patients (3.2%) had the diagnosis of
immune thrombocytopenic purpura (ITP) and
splenectomy was planned. Only one patient was
readmitted for further follow-up of DUB; the rest
(96.8%) were followed as outpatients. For the
readmitted patient, the same protocol was used by
doubling the initial dosage, and the patient responded
well.

Discussion
One of the most common gynecologic problems
during adolescence is menstrual irregularities. Demir et
al. (2) reported the incidence of DUB among adolescents
12-15 years of age as 45.5%. We found that incidence of
menstrual irregularities among adolescents of the same
age group in the outpatient Adolescent Gynecology Unit
of our hospital was about 48% (3).
This is not surprising, however, since 50 to 80% of
cycles within the first two years after menarche are
anovulatory (4). A regular menstrual pattern is generally
not established until 20 months after menarche. Regular

ovulatory periods may not occur for four or five years,
and 80% of cycles are anovulatory in the first year after
menarche (5). Many resolve spontaneously within a few
years as the hypothalamic-pituitary-ovarian axis matures.
However, if there is severe AUB requiring hospitalization
of an adolescent, one should search for a significant
medical problem.
Even in those adolescents with bleeding sufficient to
require hospitalization, in one study, 74% of cases were
secondary to DUB (6). Of the rest, 19% were secondary
to primary coagulopathies, and 7% included pregnancy
complications, oral contraceptives, trauma, systemic
illness, and malignancy.
Systemic bleeding disorders are reported in 7-20% of
women of all ages who present with menorrhagia (7). We
found this figure as 25.8% in our patient group. It is
estimated that there is an underlying coagulopathy in
20% of adolescents who require hospitalization for acute
menorrhagia, 25% who experience severe menorrhagia
and have Hb levels of <10 g/dL, 33% who require
transfusion, and 50% who hemorrhage at menarche (8).
In our study, bleeding disorder was present in 38.1% of
girls with AUB and with Hb <10 g/dL. Among the patients
with blood transfusion, 43.8% had bleeding disorder.
Our figures seemed to be slightly higher than in the
previously reported articles.
A retrospective review of outpatient and inpatient
adolescents seen at a children’s hospital for menorrhagia
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revealed that 13% had thrombocytopenia, 8% had
abnormal platelet function and 11% had inherited
coagulation
disorders.
Among
those
with
thrombocytopenia, the most common diagnoses were ITP
(55%) and chemotherapy-induced myelosuppression
(22%) (7). The most common dyscrasia in adolescents is
primary or secondary thrombocytopenic purpura (9).
Hereditary bleeding disorders, such as vWD and
Christmas disease (hemophilia B), are usually known to
exist in the family and thus are readily recognized.
However, about 25% of patients with hereditary
coagulation disorders show a negative family history
(10). In our study, the most common blood dyscrasias
were factor VII deficiency (9.7%) and thrombocytopenia
(9.7%).
Treatment of AUB is usually medical with combined
oral contraceptives or high- dose estrogen preparations
followed by progestin preparations. Hormonal therapy
will almost always stop even severe bleeding.
In hospitalized adolescents with heavy bleeding,
conjugated estrogens, 25 to 40 mg every 4 hours for 24
hours intravenously, can be used. In addition to estrogen,
a progestational agent should be used orally as either
norethindrone, 5 mg orally four times a day, or
medroxyprogesterone acetate, 5 to 10 mg four times a
day, or in the form of a progestational dominant oral
contraceptive (11). It is advisable to continue the oral
agent four times a day for 4 days, three times a day for
3 days, then twice a day for 2 weeks. Afterwards, the
adolescent should be cycled on birth control pills for
several months. Therapy usually stops bleeding within 24
hours. If it does not occur within 48 hours, the
adolescent should be reevaluated for a bleeding problem
or another organic problem.
If hormonal therapy can not control the bleeding,
which is an unusual occurrence, a dilatation and curettage
is advisable for both diagnostic and therapeutic purposes
(11). Dilatation and curettage should be reserved for the
few girls who fail with hormonal therapy. In our study,
all adolescents responded to high-dose oral contraceptive
therapy, and no intravenous hormonal therapy was
needed. Dilatation and curettage was not required for our
study group. Splenectomy for ITP, as in one of our cases,
will be necessary.
Davenas and colleagues (12) reported that the ethinyl
estradiol component appears to be responsible for
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modifications in platelet lipid metabolism during oral
contraceptive use. The response appears after a latency
period and seems to be irreversible, since the duration of
life of platelets is 4-5 days. The increased synthesis occurs
mainly in cholesterol and its precursors lanosterol and
dihydrolanosterol. Supplemental in vitro experiments
suggested that lanosterol was responsible for the
increased platelet activity (12).
Forty-three percent of the women taking oral
contraceptives showed an increased platelet sensitivity to
thrombin. The increased sensitivity was correlated with
increased lanosterol synthesis, but the relation was only
observed in women taking oral contraceptives. The
phenomenon is of interest because of its possible
relationship to the increased risk of thromboembolic
accidents in women taking oral contraceptives (12).
The Society of Obstetricians and Gynecologists of
Canada recommends that girls growing up in families
with a history of vWD or other inherited bleeding
disorders should be tested pre-menarchally to determine
whether or not they have inherited the disease to allow
both the patient and her family to prepare for her first
and subsequent menstrual periods. In adolescents
presenting with menorrhagia, an inherited bleeding
disorder should be excluded. When possible, investigation
should be undertaken before oral contraceptive therapy is
instituted, as the hormonally induced increase in factor
VIII and vWD may mask the diagnosis (13).
In an interesting 6-month controlled trial, 18 boys
with hemophilia were treated with combined estrogens
and progesterone. Findings showed a reduction in
bleeding of skin and joints, a minor shortening of
coagulation time in glass and plastic, a decrease in kaolincephalin time, and a significant increase in fibrinogen (P
value=0.041), and factor II and VII levels (P
value=0.001). However, the treatment did not affect the
number of days in bed, hematuria, epistaxis, or muscular
bleeding. All patients developed severe side effects
(gynecomastia and pubic hair); therefore, this treatment
is not recommended in management of hemophilia in
boys (14).
Another important factor for the effective treatment
of AUB in adolescent girls with oral contraceptive pills is
the continuation of the treatment. There are some
misconceptions about oral contraceptive pills in the
Turkish population, such as that oral contraceptives cause
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infertility or hormonal imbalance, and this will cause
discontinuation of the treatment. Appropriate counselling
is necessary to overcome this difficulty. We established a
special gynecological outpatient service for adolescent
girls at our hospital in 2005. An obstetrician and
gynecologist, general practitioner, clinical psychologist,
and a nurse, who have been educated in adolescent
reproductive health and counselling, are employed in the
Adolescent Gynecology Unit. A dermatologist was added
to this team in 2006. Before the establishment of this
department, we were unaware of exactly how many girls
with DUB applied to our hospital (3). However, in 2005
and 2006, the exact data regarding adolescent girls with
AUB was known, and adequate counselling was provided
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to both the adolescent girls and their parents before
initiating a treatment. We believe that presence of this
special service for adolescents affected the success of our
treatment.
In conclusion, the adolescent patient who presents
with severe dysfunctional bleeding may have a significant
medical problem like a blood dyscrasia. Medical treatment
is highly effective even in those with bleeding disorders,
probably due to the positive coagulative effect of the
estrogen component of oral contraceptives on platelets
and clotting factors. Appropriate clinical evaluation and an
individualized approach to treatment are essential for
optimal care.
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